Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

The primary objectives of this study are to characterize the safety and tolerability of evixapodlin (formerly GS-4224) and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of evixapodlin in participants with advanced solid tumors.

Key facts

Study ID

NCT04049617

Run by

Gilead Sciences

People needed

18

Starts

2019-08-26

Expected to finish

2021-03-30

Last updated by the study team

2022-10-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• California Care Associates for Research and Excellence Inc — Encinitas, California, United States
• NEXT Oncology — San Antonio, Texas, United States
• Northwest Medical Specialties, PLLC — Tacoma, Washington, United States
• Auckland City Hospital — Auckland, New Zealand
• Christchurch Clinical Studies Trust, LLC — Christchurch, New Zealand
• Auckland Clinical Studies Ltd — Grafton, Auckland, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.